Catalog No.: PC-20591Not For Human Use, Lab Use Only.
IOA-244 (Roginolisib, MSC2360844) is a potent, selective and non-ATP-competitive PI3Kδ inhibitor with IC50 of 19 nM, selective over PI3Kβ (0.43 uM), Vps34 (9 uM) and PI3Kα (10.1 uM).
IOA-244 (Roginolisib, MSC2360844) is a potent, selective and non-ATP-competitive PI3Kδ inhibitor with IC50 of 19 nM, selective over PI3Kβ (0.43 uM), Vps34 (9 uM) and PI3Kα (10.1 uM).
IOA-244 effectively inhibits proliferation of SU-DHL-6 (PI3Kδ harboring) with a GI50 of 0.24 uM.
IOA-244 limits proliferation of lymphoma cancer cells expressing high levels of PI3Kδ.
IOA-244 inhibits regulatory T cell proliferation while having limited antiproliferative effects on conventional CD4+ T cells and no effect on CD8+ T cells.
IOA-244 sensitized the tumors to anti-PD-1 treatment in CT26 colorectal and Lewis lung carcinoma lung cancer models, with similar activity in the Pan-02 pancreatic and A20 lymphoma syngeneic mouse models.
